Cerveau Technologies Announces Collaboration With Banner Health
Published: Sep 20, 2017
BOSTON--(BUSINESS WIRE)--Cerveau Technologies Inc. today announced a research collaboration with Banner Health to support various research projects studying the stages of Alzheimer’s disease and other neurodegenerative diseases. These research projects will utilize an investigational imaging agent (MK-6240) to be used in positron emission tomography (PET) scans for assessing the status and progression of neurofibrillary tangles (NFTs) in the brain. NFTs made up of aggregated tau protein are a hallmark of several neurodegenerative diseases, including Alzheimer’s disease.
“We are delighted to be working with Cerveau to advance the study of Alzheimer's using their promising tau PET tracer," said Eric Reiman, MD, executive director at Banner Alzheimer's Institute and CEO of Banner Research. "Amyloid, tau and other biomarkers will play increasingly important roles in the understanding of and fight against this terrible disease."
As part of the agreement, Cerveau will support various research projects and transfer to Banner Health the technology for production of [18F]MK- 6240 needed for the initiatives.
“Cerveau is excited to be working with Dr. Reiman and his colleagues to better understand tau pathology,” said Rick Hiatt, President of Cerveau Technologies, Inc., “The partnership with Banner Health is another important step forward in our strategy of developing an international network of key collaborators and production sites to enable broad access for scientific research and clinical trial support.”
About Cerveau Technologies, Inc.
Cerveau Technologies, Inc. is a partnership between Enigma Biomedical Group, Inc. and Sinotau Pharmaceutical Group. Cerveau's vision is to globally develop diagnostics and technology that positively impact patients with neurodegenerative disorders including Alzheimer's disease.
About Banner Alzheimer’s Institute
Through its research and care, Banner Alzheimer’s Institute is dedicated to the goal of ending Alzheimer’s disease without losing another generation. Founded in 2006 by Banner Health, one of the country’s largest nonprofit health care systems, BAI has a three-fold focus: to conduct revolutionary studies in the detection, treatment and prevention of Alzheimer’s; to set a national standard of patient and family care; and to forge scientific collaborations that bring together institutions and disciplines internationally. For more information, visit www.banneralz.org.
Cerveau Technologies, Inc.
Rick Hiatt, 617-906-2715